Enveda Turns Nature’s Chemistry Into New Medicines

Enveda is building a drug-discovery system around a stubborn fact: nature has spent billions of years making chemistry, while pharmaceutical research has studied only a sliver of it.

Founded in 2019 by Viswa Colluru, PhD, the Boulder-based clinical-stage biotechnology company uses mass spectrometry, machine learning, chemistry models, and automated laboratories to find natural molecules and turn them into potential medicines. Colluru is Enveda’s founder and CEO. Pieter Dorrestein, PhD, is the scientific co-founder and an advisor.

Enveda matters now because the platform has moved beyond an elegant scientific thesis. Its current pipeline includes 3 clinical assets across 4 indications, 6 IND-enabling assets, and 17 development candidates. A $311M Series E announced in September 2026 gives the company more capital to advance that pipeline, but the larger test is already underway in human trials.

About Enveda

Enveda starts with natural chemistry that conventional drug discovery has struggled to use at scale. A plant sample can contain thousands of molecules. Historically, identifying each molecule, separating it, determining its structure, and testing its biological activity could turn discovery into a slow and expensive scavenger hunt.

Enveda’s platform is designed to collapse those steps. The company combines mass spectrometry with proprietary machine-learning systems and large language models for chemistry, including its PRISM foundation model. It then connects predicted molecular structures to biological activity and uses automated laboratories to screen promising compounds.

The output is what Enveda calls a “library of life,” a searchable catalog of natural molecules and their potential functions. The phrase sounds poetic, but the operating idea is concrete: make natural chemistry computable enough for modern drug hunters to search, compare, and optimize.

How Enveda’s Platform Works

Enveda’s platform is organized around 3 jobs: organize natural molecules, translate their chemical information, and apply that knowledge to disease biology. The company says its systems can analyze thousands of molecules at once rather than isolating them one at a time.

Enveda reports that its approach reaches development-candidate selection 4x faster than a cited industry benchmark, requires 75% fewer analogs per development candidate, and produces an 11x higher success rate per scaffold against another benchmark. Those are company comparisons, not independent clinical outcomes. They are useful because they show where Enveda believes its advantage lives: not in making a prettier prediction, but in reducing the number of experimental turns required to produce a viable drug candidate.

That distinction matters. AI drug discovery is crowded with platforms that promise speed at the beginning of the funnel. Enveda is attempting to prove that advantage further downstream, where chemistry meets formulation, toxicology, clinical operations, and patients. Biology remains unimpressed by pitch decks.

The Clinical Pipeline Is the Real Scoreboard

The current Enveda pipeline lists 3 clinical assets across 4 indications. ENV-294 is in Phase 2a trials for atopic dermatitis and asthma after completing Phase 1b work in atopic dermatitis. ENV-308 is in Phase 1 for post-weight-loss maintenance. ENV-6946 is in Phase 1 for inflammatory bowel disease.

Enveda also reports 6 IND-enabling assets and 17 development candidates. Those programs give the platform multiple opportunities to produce evidence, but they also multiply the burden of execution. Every clinical asset requires manufacturing, regulatory work, trial design, patient recruitment, data quality, and capital. A discovery engine becomes a biotechnology company when it must do all of those jobs at once.

The programs remain investigational. Early safety and activity readouts can narrow uncertainty, but they do not establish approval, broad efficacy, or commercial success. For Enveda, the next phase is less about proving that nature contains interesting molecules and more about proving that its system can repeatedly turn them into medicines.

Leadership and an East-West Operating Model

Colluru founded Enveda after working at Recursion and began with $55K of personal savings, according to the company’s current leadership biography. The executive team now spans technology, science, development, finance, people, and operations. August Allen serves as CTO, Hannah Gordon, PhD, as Chief Scientific Officer, Daniel Wee, PhD, as Chief eXecution Officer, and Niranjan Rao, PhD, FCP, as Chief Development Officer.

Enveda operates from Boulder and Genome Valley in Hyderabad, India. That footprint is central to the company’s identity rather than a back-office arrangement. The organization combines software and laboratory automation with medicinal chemistry, clinical development, and a research tradition rooted in natural products.

The name reflects that bridge. Enveda combines “enable” with “veda,” the Sanskrit word for knowledge. The company’s stated values, Curiosity, Agency, Journey, Charity, and Unity, translate the mission into a hiring filter: people who challenge assumptions, own work, respect the process, take care of colleagues, and operate as one team.

Funding Changes the Scale, Not the Science

The company’s September 2026 Series E brought in $311M and pushed company-reported capital raised above $845M. Catalio Capital Management led the round. Quartz reported that the financing valued Enveda at about $2B.

That capital can support later-stage development, additional clinical entries, and continued expansion of the discovery platform. It also raises the standard of proof. The market is no longer evaluating a promising natural-products database. Investors are underwriting a multi-asset clinical organization that must allocate capital across programs without letting platform ambition outrun evidence.

Enveda’s strategic advantage could come from having both halves under one roof. Clinical results can sharpen discovery priorities, while a broader chemical library can keep feeding the pipeline. The risk is equally obvious: discovery platforms and clinical programs consume different kinds of talent, time, and managerial attention.

Hiring Is an Execution Signal

Enveda’s careers page currently invites candidates to join the company, although it does not provide a stable public count of open positions. The relevant signal is the range of capabilities the business must keep assembling: computational science, laboratory automation, medicinal chemistry, clinical development, regulatory operations, and corporate infrastructure.

Hiring across those functions is not a victory lap. It is evidence of the work required to move from discovering molecules to running trials. The company describes benefits including flexible paid time off, a year-end company break, paid parental leave, adoption assistance, and work-from-home support. Those policies sit alongside a culture that calls for “learn-it-alls, not know-it-alls,” an appropriate posture for a business trying to translate chemistry science has not fully mapped.

Enveda also states that its biodiversity work follows access-and-benefit-sharing provisions aligned with the Convention on Biological Diversity. As natural chemistry becomes a commercial data asset, responsible sourcing and benefit sharing are not side notes. They are part of the legitimacy of the platform.

What Enveda Signals for AI Drug Discovery

The durable AI drug-discovery companies will not be judged by model vocabulary. They will be judged by molecules, trial data, and whether their systems improve the odds or economics of reaching patients.

Enveda has crossed an important threshold because its thesis is now exposed to that scoreboard. The company has a differentiated source of chemical diversity, an integrated technical and laboratory platform, 3 assets in clinical development, and enough capital to pursue later-stage evidence. None of that guarantees a medicine. It does make Enveda one of the clearer tests of whether AI can expand drug discovery beyond familiar synthetic chemical space.

Nature has already done the long experiment. Enveda’s job is to read the results accurately, choose the right molecules, and survive the much less poetic work that follows.